Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Oct 2019
Historique:
pubmed: 28 6 2019
medline: 7 1 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

Objective Hepcidin is a master iron regulator hormone produced by the liver, but precise mechanism underlying its involvement in iron overload in hepatitis C virus (HCV) infection remains unclear. We investigated the serum hepcidin levels against iron overload before and after HCV eradication. Methods We prospectively investigated the iron metabolism characteristics in 24 patients with HCV genotype 1b infection before and after treatment. We also assessed the serum erythroferrone (ERFE) levels to investigate its association with iron metabolism changes. Patients were treated with Ledipasvir 90 mg and Sofosbuvir 400 mg once daily for 12 weeks and observed for 12 more weeks in order to evaluate their sustained virological response. Results Serum hepcidin levels at baseline were in the normal range, although serum ferritin levels were increased. After HCV eradication, both serum ferritin and hepcidin levels were significantly decreased at 24 weeks from baseline (p<0.001, p=0.006, respectively). However, the serum hepcidin-to-ferritin ratios were significantly increased (p<0.001). In addition, the serum ERFE levels were significantly decreased (p<0.001). Increases in the serum hepcidin-to-ferritin ratios were correlated with decreases in the serum ERFE levels (ρ=-0.422, p=0.039). Conclusion Serum hepcidin levels were relatively low against ferritin levels in HCV infection. However, after HCV eradication, the serum hepcidin-to-ferritin ratios were increased. These results indicate the improvement of inadequate hepcidin secretion against iron overload after HCV eradication. Downregulation of ERFE may have affected the improvement of iron metabolism.

Identifiants

pubmed: 31243222
doi: 10.2169/internalmedicine.2909-19
pmc: PMC6859405
doi:

Substances chimiques

Antiviral Agents 0
Benzimidazoles 0
Erfe protein, human 0
Fluorenes 0
HAMP protein, human 0
Hepcidins 0
Peptide Hormones 0
ledipasvir, sofosbuvir drug combination 0
Ferritins 9007-73-2
Iron E1UOL152H7
Uridine Monophosphate E2OU15WN0N
Sofosbuvir WJ6CA3ZU8B

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2915-2922

Références

Nat Genet. 2014 Jul;46(7):678-84
pubmed: 24880340
Free Radic Biol Med. 2003 Oct 1;35(7):826-32
pubmed: 14583347
J Hepatol. 2009 Nov;51(5):845-52
pubmed: 19729219
Haematologica. 2017 Feb;102(2):260-270
pubmed: 28143953
Blood. 2011 Apr 28;117(17):4425-33
pubmed: 21346250
Blood Cells Mol Dis. 2016 May;58:45-51
pubmed: 27067488
Hepatology. 2008 Nov;48(5):1420-9
pubmed: 18671304
Res Commun Mol Pathol Pharmacol. 2000;107(1-2):39-44
pubmed: 11334369
Am J Gastroenterol. 2001 Aug;96(8):2487-8
pubmed: 11513196
Hepatology. 2000 Apr;31(4):997-1004
pubmed: 10733558
Lab Invest. 1997 Mar;76(3):365-74
pubmed: 9121119
Curr Opin Hematol. 2015 May;22(3):199-205
pubmed: 25710710
J Gastroenterol Hepatol. 2017 Apr;32(4):864-869
pubmed: 27637864
J Gastroenterol Hepatol. 2014 Feb;29(2):387-94
pubmed: 23926964
Hepatology. 2012 Aug;56(2):492-500
pubmed: 22334511
BMC Cancer. 2008 Jun 09;8:167
pubmed: 18541040
Biosci Rep. 2017 Nov 29;37(6):null
pubmed: 29097483
Gastroenterology. 2008 Jan;134(1):226-38
pubmed: 18166355
Blood. 2017 Sep 7;130(10):1243-1246
pubmed: 28739636
Blood. 2006 Aug 15;108(4):1381-7
pubmed: 16621968
Kidney Int. 2010 Oct;78(8):769-73
pubmed: 20668427
Am J Physiol Regul Integr Comp Physiol. 2015 Feb 15;308(4):R330-5
pubmed: 25519735
Physiol Rev. 2013 Oct;93(4):1721-41
pubmed: 24137020
J Hepatol. 2008 Nov;49(5):702-10
pubmed: 18620776
Gastroenterology. 2006 Nov;131(5):1440-51
pubmed: 17101320
J Hepatol. 2016 Feb;64(2):505-515
pubmed: 26596411

Auteurs

Shinjiro Inomata (S)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Meotoiwa Hospital, Japan.

Akira Anan (A)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Shiida Clinic, Japan.

Eri Yamauchi (E)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Ryo Yamauchi (R)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Hideo Kunimoto (H)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Kazuhide Takata (K)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Takashi Tanaka (T)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Keiji Yokoyama (K)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Daisuke Morihara (D)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Yasuaki Takeyama (Y)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Makoto Irie (M)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Division of Gastroenterology, Fukuoka University Nishijin Hospital, Japan.

Satoshi Shakado (S)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Tetsuro Sohda (T)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Department of Hepatology, Red Cross Fukuoka Hospital, Japan.

Shotaro Sakisaka (S)

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH